

Certificate of Analysis

TAO3, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-745, 14-745-K, 14-745M

Parent Lot # D7BN007U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, human TAO3 amino acids 1–411. Expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 87.4% by SDS-PAGE and Coomassie blue staining. MW = 50.2kDa

Specific Activity (Parent lot# D7BN007U): 1084U/mg, where one unit of TAO3, active activity is defined as 1nmol phosphate incorporated into 0.8mg/ml myelin basic protein per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 2.788mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 2.3–10.5ng of this lot of enzyme phosphorylated 0.8mg/ml myelin basic protein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as TAO3 with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Substrate: Myelin Basic Protein (MBP):** Use at a final assay concentration of 0.8mg/ml. Make up an 8.0mg/ml stock. Use 2.5µl of stock solution per assay point.
3. **NaCl:** Use at a final assay concentration of 200mM. Make a 3M stock. Add 1.67µl of stock per assay point.
4. **TAO3, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1 mg/ml BSA. Use 2.3–10.5ng per assay point.
5. **[γ -³³P] ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **myelin basic protein**.
3. Add **2.5µl (2.3–10.5ng) TAO3, active**.
4. Add 1.67µl of 3M NaCl.
5. Add 3.33µl of dH₂O.
6. Add 10µl of diluted [γ -³³P] ATP mixture.
7. Incubate for 10 minutes at 30°C.
8. Stop the reaction by adding 5µl of 3% phosphoric acid.
9. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
10. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
11. Wash the filtermat once for 2 minutes with methanol.
12. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
13. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

TAO3 Sequence Information

<u>Protein</u>	Human TAO3
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M31 of recombinant sequence = M1 of native human TAO3
<u>Accession number</u>	GenBank NM_016281. The recombinant protein contains the amino acid substitution N47S with reference to NM-016281. This mutation is reported in GenBank BC002756 and BC7007185

Recombinant TAO3 amino acid sequence:

```

1 MSYYHHHHH DYDIPTTENL YFQGAMDPEF MRKGVLDKDE IADLFYKDDP EELFIGLHEI
61 GHGSFGAVYF ATNAHTSEVV AIKKMSYSGK QTHEKWQDIL KEVKFLRQLK HPNTIEYKGC
121 YLKEHTAWLV MEYCLGSASD LLEVHKKPLQ EVEIAAITHG ALHGLAYLHS HALIHRDIKA
181 GNILLTEPGQ VKLADFGSAS MASPANSFVG TPYWMAPEVI LAMDEGQYDG KVDIWSLGIT
241 CIELAERKPP LFNMNAMSAL YHIAQNDSPT LQSNEWTDSF RRFVDYCLQK IPQERPTSAE
301 LLRHDFVRRD RPLRVLIDLI QRTKDAVREL DNLQYRKMKK ILFQETRNGP LNESQEDEED
361 SEHGTSLNRE MDSLGSNHSI PSMSVSTGSQ SSSVNSMQEV MDESSSELVM MHDDESTINS
421 SSSVVHKKDH VFIRDEAGHG D

```

Recombinant TAO3 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgccatgga tccggaattc atgcgtaaag ggggtgctgaa ggaccagag
121 attgccgatc tattctacaa agatgatcct gaggaacttt ttattgggtt gcatgaaatt
181 ggacatggaa gttttggagc agtttatttt gctacaaatg ctacaccagc tgagggtggtg
241 gcaattaaga agatgtccta tagtgggaag cagacccatg agaaatggca agatattctt
301 aaggaagtta aatttttacg acaattgaag catcctaata ctattgagta caaaggctgt
361 tacttgaaag aacacactgc ttggttggtg atggaatatt gcttaggctc agcctctgat
421 ttattagaag ttcataaaaa accacttcag gaagtggaga tcgctgccat tactcatgga
481 gccttgcatg gactagccta cctacattct catgcattga ttcataggga tattaagca
541 ggaaatattc ttctaacaga gccaggctcag gtaaaactag ctgattttgg atctgcttca
601 atggcttctc ctgccaactc cttcgtgggc acaccttact ggatggctcc agagggtgatc
661 ttagctatgg atgaaggaca gtatgatggg aaagttgata tttggtcact tggcatcact
721 tgtattgaat tggcggaaac gaagccgcc cttttcaaca tgaatgcaat gagtgcctta
781 tatcacattg ccagaaatga ctcccaacg ttacagtcta atgaatggac agactccttt
841 aggagatttg ttgattactg cttgcagaaa atacctcagg aaaggccaac atcagcagaa
901 ctattaaggc atgactttgt tcgacgagac cggccactac gtgtcctcat tgacctcata
961 cagaggacaa aagatgcagt tcgtgagcta gataacctac agtaccgaaa aatgaaaaaa
1021 atacttttcc aagagacacg gaatggacc ttgaatgagt cacaggagga tgaggaagac
1081 agtgaacatg gaaccagcct gaacagggaa atggacagcc tgggcagcaa ccattccatt
1141 ccaagcatgt ccgtgagcac aggcagccag agcagcagtg tgaacagcat gcaggaagtc
1201 atggacgaga gcagttccga acttgcagat atgcacgatg acgaaagcac aatcaattcc
1261 agctcctccg tcgtgcataa gaaagatcat gtattcataa gggatgaggc gggccacggc
1321 gattaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services